Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTISITE vs AMZEEQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.
Topical antibiotic and anti-inflammatory: inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and reduces pro-inflammatory cytokine production.
Treatment of periodontal disease (adjunct to scaling and root planing),Topical treatment of infected wounds and skin ulcers
FDA-approved for the treatment of inflammatory lesions of rosacea
Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.
Apply a thin layer to affected areas twice daily (morning and evening). Topical, 1.5% w/w.
Not applicable due to local degradation; systemic half-life is negligible as tetracycline hydrochloride is not absorbed.
Terminal half-life is approximately 28 days due to accumulation in the skin and hair follicles; clinical context: supports once-weekly dosing.
Not significantly metabolized; primarily excreted unchanged in urine and feces.
Minimal systemic absorption; not extensively metabolized.
Primarily eliminated by phagocytic degradation at the application site; minimal systemic absorption, negligible renal or biliary excretion.
Renal: 30% as unchanged drug; Fecal: 70% as metabolites and unchanged drug via biliary excretion.
Not applicable (no systemic absorption); if systemically present, tetracycline is 50-60% bound to plasma proteins.
99% bound to plasma proteins, primarily albumin and lipoproteins.
Not applicable due to lack of systemic absorption; if systemic, tetracycline Vd is 1.3-1.6 L/kg.
Approximately 12 L/kg, indicating extensive distribution into tissues including skin and sebaceous glands.
Negligible systemic bioavailability (<0.1%) when applied topically; not administered orally or intravenously for periodontal use.
Topical: Minimal systemic absorption, approximately 1% of applied dose.
Not systemically absorbed; no renal adjustment required.
No dosage adjustment required for renal impairment.
Not systemically absorbed; no hepatic adjustment required.
No dosage adjustment required for hepatic impairment.
Safety and efficacy not established in pediatric patients.
Not recommended for patients under 12 years of age; safety and efficacy not established.
No specific dose adjustment; use standard adult dosing with caution for age-related comorbidities.
No specific dose adjustment; use same as adults with caution for skin fragility.
None
No black box warning.
Photosensitivity,Superinfection with resistant organisms,Use in renal impairment may require dose adjustment,Not recommended in children under 8 years due to permanent tooth discoloration
Use may result in overgrowth of nonsusceptible organisms including fungi.,Avoid contact with eyes, mouth, and mucous membranes.,Not for oral, ophthalmic, or intravaginal use.
Hypersensitivity to tetracyclines,Severe renal impairment
Hypersensitivity to any component of the formulation.
No direct food interactions. Avoid eating on the treated side to prevent dislodgement of the fiber. Maintain soft diet to minimize trauma. Avoid alcohol-based mouthwashes.
No significant food interactions reported with topical AMZEEQ. However, oral minocycline absorption is affected by dairy products; for topical foam, no dietary restrictions are necessary.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, reduced fetal weight) at doses 1-2 times the human dose. First trimester: potential for teratogenicity (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus; also potential for inhibition of fetal bone growth and maternal hepatotoxicity. Use only if potential benefit outweighs risk.
Limited human data; animal studies show no teratogenic effects at systemic exposures up to 1.7 times the MRHD. No known fetal risk; avoid first trimester due to theoretical risk from systemic absorption.
Tetracycline is excreted in human milk (M/P ratio approximately 0.6-1.5). Due to potential for serious adverse reactions (tooth discoloration, bone growth inhibition, photosensitivity) in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Avoid prolonged use during breastfeeding.
Unknown if excreted in human milk; M/P ratio not available. Use with caution; avoid application to breast area.
No specific dose adjustments for ACTISITE (tetracycline periodontal fiber). Systemic absorption minimal (peak serum concentrations <0.1 mcg/m L). Pregnancy may alter pharmacokinetics of tetracycline (increased volume of distribution, decreased protein binding), but due to local administration, systemic effects are negligible. No dosage adjustment required for the fiber formulation; however, avoid systemic tetracycline use during pregnancy when possible.
No dosage adjustment required; pharmacokinetics in pregnancy not studied.
ACTISITE (tetracycline hydrochloride) periodontal fiber is a controlled-release local antibiotic for adjunctive treatment of chronic periodontitis. Insert fiber into periodontal pocket to deliver drug over 10 days. Ensure pocket depth is ≥5mm. Do not use with metallic or synthetic fibers. Fiber must be secured with cyanoacrylate adhesive. Monitor for foreign body sensation, pain, or infection. Removal at 10 days is mandatory to avoid excessive tissue reaction. Not for acute abscesses.
AMZEEQ (minocycline) 4% foam is a topical antibiotic indicated for inflammatory lesions of rosacea. Avoid contact with eyes and mucous membranes. Use once daily. May cause skin yellowing (pseudolacte) and hyperpigmentation, especially in dark-skinned patients. Consider sunscreen use due to photosensitivity risk. Not for oral administration.
Do not brush or floss the treated area while the fiber is in place.,Avoid chewing hard or sticky foods on the treated side.,You may feel a mild foreign body sensation; report severe pain or swelling.,The fiber must be removed after 10 days; do not leave it longer.,Complete the full course of prescribed oral hygiene and antibiotics if given.
Apply foam to affected areas of face once daily, avoiding eyes and mouth.,Wash hands after application.,May cause temporary yellowing of skin or fingernails; not harmful.,Use sunscreen and protective clothing to prevent sunburn.,Do not swallow or apply to large skin areas.,Inform doctor if pregnant, breastfeeding, or planning pregnancy.,Avoid using other topical products on treated areas unless directed by doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTISITE vs AMZEEQ, answered by our medical review team.
ACTISITE is a Tetracycline Antibiotic that works by Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.. AMZEEQ is a Tetracycline Antibiotic that works by Topical antibiotic and anti-inflammatory: inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and reduces pro-inflammatory cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTISITE and AMZEEQ depend on the specific clinical indication. These are both Tetracycline Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTISITE is: Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.. The standard adult dose of AMZEEQ is: Apply a thin layer to affected areas twice daily (morning and evening). Topical, 1.5% w/w.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTISITE and AMZEEQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTISITE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, red. AMZEEQ is classified as Category C. Limited human data; animal studies show no teratogenic effects at systemic exposures up to 1.7 times the MRHD. No known fetal risk; avoid first trimester due to theoretical risk fr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.